Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus NUVESSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus NUVESSA.
NORGESTIMATE AND ETHINYL ESTRADIOL vs NUVESSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
NUVESSA (bupivacaine liposomal) is a local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. The liposomal formulation provides sustained release of bupivacaine.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
5 mg orally once daily.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Terminal elimination half-life is approximately 24 hours (range 18-30 hours) in healthy adults. This supports once-daily dosing; however, half-life may be prolonged in patients with renal impairment.
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Primarily renal excretion of unchanged drug and metabolites (approximately 70% of the dose), with about 20% eliminated via biliary/fecal routes. Less than 10% is recovered as unchanged drug in urine.
Category D/X
Category C
Estrogen
Estrogen